Rabbit Recombinant Monoclonal JAK2 antibody. Carrier free. Suitable for IP, WB, ICC/IF and reacts with Human, Mouse, Rat samples.
Constituents: PBS
IP | WB | IHC-P | ICC/IF | |
---|---|---|---|---|
Human | Tested | Tested | Not recommended | Tested |
Mouse | Expected | Tested | Not recommended | Expected |
Rat | Expected | Tested | Not recommended | Expected |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Select an associated product type
Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin receptor (MPL/TPOR); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins (PubMed:15690087, PubMed:7615558, PubMed:9657743, PubMed:15899890). Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins (PubMed:15690087, PubMed:9618263). Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain (PubMed:9657743). Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. Part of a signaling cascade that is activated by increased cellular retinol and that leads to the activation of STAT5 (STAT5A or STAT5B) (PubMed:21368206). In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation (PubMed:20098430). Plays a role in cell cycle by phosphorylating CDKN1B (PubMed:21423214). Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin (PubMed:19783980). Up-regulates the potassium voltage-gated channel activity of KCNA3 (PubMed:25644777).
Tyrosine-protein kinase JAK2, Janus kinase 2, JAK-2, JAK2
Rabbit Recombinant Monoclonal JAK2 antibody. Carrier free. Suitable for IP, WB, ICC/IF and reacts with Human, Mouse, Rat samples.
Constituents: PBS
ab170718 is the carrier-free version of Anti-JAK2 antibody [EPR108(2)] ab108596.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
JAK2 also known as Janus kinase 2 is a protein tyrosine kinase with a molecular weight of 125 kDa. It plays an essential mechanical role in the signaling pathways by acting as an intermediary between cell surface receptors and intracellular signaling molecules. The JAK2 protein binds to certain cytokine receptors facilitating signal transduction necessary for various cellular responses. JAK2 is expressed in many tissues including hematopoietic cells which are associated with the blood and immune systems.
JAK2 is important for transmitting signals that dictate cell growth survival and differentiation within the hematopoietic system. It operates bodily functions by forming complexes with specific phosphorylation sites on its associated receptors. Through this formation JAK2 influences the signaling cascade particularly by interacting with other signal transducers and activators where it phosphorylates and becomes activated. This action affects gene transcription directly correlated with cellular proliferation and differentiation processes.
The function of JAK2 integrates into the JAK-STAT signaling pathway which is an important pathway in the regulation of immune function growth and development. It works in conjunction with proteins such as STAT3 and STAT5 to transmit signals from cytokine receptors to the nucleus. This pathway critically impacts responses like inflammation and hematopoiesis aligning with its role in precursor proliferation within the bone marrow and various immune cells’ function.
JAK2 has significant implications in conditions like myeloproliferative neoplasms and polycythemia vera. Mutations in the JAK2 gene notably the JAK2 V617F mutation lead to uncontrolled cell division as they disrupt normal signaling mechanisms often resulting in blood cell disorders. In these contexts JAK2 interacts with proteins such as EpoR and MPL which play roles within these disease pathways. Understanding how JAK2 mutations contribute to disease progression offers pathways for targeted therapies.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using the same antibody clone in a different buffer formulation (Anti-JAK2 antibody [EPR108(2)] ab108596).
Lanes 1- 4: Merged signal (red and green). Green - Anti-JAK2 antibody [EPR108(2)] ab108596 observed at 131 kDa. Red - Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) observed at 37 kDa.
Anti-JAK2 antibody [EPR108(2)] ab108596 was shown to react with JAK2 in wild-type A549 cells in western blot. Loss of signal was observed when knockout cell line Human JAK2 knockout A549 cell line ab267113 (knockout cell lysate Human JAK2 knockout A549 cell lysate ab256963) was used. Wild-type A549 and JAK2 knockout A549 cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. Anti-JAK2 antibody [EPR108(2)] ab108596 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-JAK2 antibody [EPR108(2)] (Anti-JAK2 antibody [EPR108(2)] ab108596) at 1/1000 dilution
Lane 1: Wild-type A549 cell lysate at 20 µg
Lane 2: JAK2 knockout A549 cell lysate at 20 µg
Lane 2: Western blot - Human JAK2 knockout A549 cell line (Human JAK2 knockout A549 cell line ab267113)
Lane 3: K562 cell lysate at 20 µg
Lane 4: Daudi cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 131 kDa
Observed band size: 131 kDa
Immunocytochemistry/ Immunofluorescence analysis of K562 (Human chronic myelogenous leukemia cell line from bone marrow) cells labeling JAK2 with purified Anti-JAK2 antibody [EPR108(2)] ab108596 at 1/150 dilution (8.5μg/ml). Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077, a goat anti-rabbit IgG(Alexa Fluor® 488) was used as the secondary antibody at 1/1000 dilution. Alexa Fluor® 594 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker ab195889, anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) was used as the counter stain at 1/200 (2.5 μg/ml). PBS instead of the primary antibody was the negative control. DAPI was used as a nuclear counterstain.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-JAK2 antibody [EPR108(2)] ab108596).
Anti-JAK2 antibody [EPR108(2)] ab108596 at 1/500 dilution (3.0µg/ml) immunoprecipitating JAK2 in K562 (Human chronic myelogenous leukemia lymphoblast) cell lysate.
Lane 1 (input): K562(Human chronic myelogenous leukemia lymphoblast) whole cell lysate 10µg
Lane 2 (+): K562 whole cell lysate, 350µg + Anti-JAK2 antibody [EPR108(2)] ab108596, 2µg
Lane 3 (-): K562 cell lysate, 350µg + rabbit IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730), 2µg
For western blotting, VeriBlot for IP Detection Reagent (HRP) ab131366 VeriBlot for IP (HRP) was used at 1/1000.
Blocking and dilution buffer: 5% NFDM/TBST.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-JAK2 antibody [EPR108(2)] ab108596).
All lanes: Immunoprecipitation - Anti-JAK2 antibody [EPR108(2)] (Anti-JAK2 antibody [EPR108(2)] ab108596)
Predicted band size: 131 kDa
Observed band size: 130 kDa
Immunocytochemistry/Immunofluorescence analysis of Jurkat (Human T cell leukemia cells from peripheral blood) cells labelling JAK2 with unpurified Anti-JAK2 antibody [EPR108(2)] ab108596 at 1/300 (7.0 μg/mL). Cells were fixed with 4% Paraformaldehydeand permeabilized with 0.1% Triton X-100. Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077, Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000, 2 μg/mL) was used as the secondary antibody. Nuclei were stained with DAPI (blue).
Confocal image showing nuclear and cytoplasmic staining on Jurkat cell line.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-JAK2 antibody [EPR108(2)] ab108596).
Immunocytochemistry/Immunofluorescence analysis of Ramos (Human Burkitt's lymphoma) cells labelling JAK2 with unpurified 108596 at 1/300 (7.0 μg/mL). Cells were fixed with 4% Paraformaldehyde and permeabilized with 0.1% Triton X-100. Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077, Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000, 2 μg/mL) was used as the secondary antibody. Nuclei were stained with DAPI (blue).
Confocal image showing nuclear and cytoplasmic staining on Ramos cell line.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-JAK2 antibody [EPR108(2)] ab108596).
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com